The Technical Analyst
Crinetics Pharmaceuticals [CRNX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Crinetics Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-2.27% $43.01
America/New_York / 18 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 3 351.75 mill |
| EPS: | -3.69 |
| P/E: | -11.66 |
| Earnings Date: | May 02, 2024 |
| SharesOutstanding: | 77.93 mill |
| Avg Daily Volume: | 0.818 mill |
| RATING 2024-04-18 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -11.66 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -1.98x |
| Company: PE -11.66 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-4.87 (-111.32%) $-47.88 |
| Date: 2024-04-18 |
| Expected Trading Range (DAY) |
|---|
|
$ 40.54 - 45.48 ( +/- 5.75%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-15 | Pizzuti Dana | Sell | 14 375 | Stock option (Right to Buy) |
| 2024-04-15 | Pizzuti Dana | Buy | 14 375 | Common Stock |
| 2024-04-15 | Pizzuti Dana | Sell | 14 375 | Common Stock |
| 2024-04-15 | Struthers Richard Scott | Buy | 20 000 | Common Stock |
| 2024-04-15 | Struthers Richard Scott | Sell | 20 000 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 20.36 |
| Last 99 transactions |
| Buy: 1 549 659 | Sell: 1 109 015 |
Forecast:
16:00 - $43.01
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $43.01
Forecast 2: 16:00 - $43.01
Forecast 3: 16:00 - $43.01
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $43.01 (-2.27% ) |
| Volume | 0.525 mill |
| Avg. Vol. | 0.818 mill |
| % of Avg. Vol | 64.18 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CRNX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $38.53 | N/A | Active |
|---|
CRNX
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Latest Press Releases
2024-04-11 16:05:00 - Press Release
Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
San diego, april 11, 2024 (globe newswire) -- crinetics pharmaceuticals, inc. (nasdaq: crnx) today announced that on april 10, 2024, the compensation committee of crinetics' board of directors granted non-qualified stock option awards to purchase an aggregate of 121,300 shares of its common stock to ten new non-executive employees under the crinetics pharmaceuticals, inc. 2021 employment inducement incentive award plan (the “2021 inducement plan”). the stock options were granted as inducements material to the employees entering into employment with crinetics in accordance with nasdaq listing rule 5635(c)(4).
2024-03-19 06:00:00 - Press Release
Crinetics' Once-daily Oral Paltusotine Achieved The Primary And All Secondary Endpoints In The Phase 3 Pathfndr-2 Study In Acromegaly Patients
56% of participants on paltusotine achieved igf-1 ≤1.0 xuln vs. 5% on placebo (p
2024-03-12 16:05:00 - Press Release
Crinetics Announces Positive Topline Results From Phase 2 Trial Of Paltusotine For The Treatment Of Carcinoid Syndrome
Paltusotine treatment demonstrated rapid and sustained reductions in frequency and severity of flushing episodes and bowel movements
2024-03-11 16:05:00 - Press Release
Crinetics Pharmaceuticals Announces March 2024 Inducement Grants Under nasdaq Listing Rule 5635(c)(4)
San diego, march 11, 2024 (globe newswire) -- crinetics pharmaceuticals, inc. (nasdaq: crnx) today announced that on march 10, 2024, the compensation committee of crinetics' board of directors granted non-qualified stock option awards to purchase an aggregate of 42,450 shares of its common stock to five new non-executive employees under the crinetics pharmaceuticals, inc. 2021 employment inducement incentive award plan (the “2021 inducement plan”). the stock options were granted as inducements material to the employees entering into employment with crinetics in accordance with nasdaq listing rule 5635(c)(4).
2024-02-28 16:05:00 - Press Release
Crinetics Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Provides Corporate Update
Phase 3 pathfndr-2 study topline results expected in march 2024; pending results, nda submission in acromegaly anticipated 2h 2024
Latest News
2024-04-03 13:47:03 - CNBC Television
Under-the-radar biotech bets
Michelle Ross, StemPoint Capital CIO, joins CNBC's Halftime Report' to discuss her latest biotech pick.
2024-03-20 12:51:05 - Zacks Investment Research
Crinetics (CRNX) Up as Second Acromegaly Study Meets Goals
Crinetics (CRNX) stock rises after achieving goals in the second late-stage study evaluating paltusotine in patients with acromegaly who are treatment-naive or not currently receiving medical therapy.
2024-03-20 06:15:16 - Zacks Investment Research
Crinetics Pharmaceuticals (CRNX) Stock Jumps 19.1%: Will It Continue to Soar?
Crinetics Pharmaceuticals (CRNX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
2024-02-29 14:20:37 - Seeking Alpha
Crinetics: Paltusotine's Phase 3 Triumph Transforms Trajectory (Rating Upgrade)
2024-02-29 05:46:03 - Seeking Alpha
Crinetics Pharmaceuticals, Inc. (CRNX) Q4 2023 Earnings Call Transcript
2024-02-14 16:05:00 - GlobeNewsWire
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
SAN DIEGO, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report fourth quarter and full year 2023 financial results on Wednesday, February 28, 2024, after the close of the U.S. financial markets. Company management will host a conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a business update.
2023-11-28 15:36:20 - Seeking Alpha
Crinetics Pharmaceuticals: Some Caution Warranted
Today, we take a deeper look at Crinetics Pharmaceuticals, Inc., which has seen a significant increase in its stock price in recent months. The company's primary drug candidate, paltusotine, looks like it could become a best of breed treatment for the rare disease acromegaly. Crinetics is also evaluating paltusotine for the treatment of Carcinoid syndrome and has other compounds in development for different diseases.
2023-11-20 16:05:00 - GlobeNewsWire
Crinetics Pharmaceuticals to Participate in Upcoming Investor Conferences
SAN DIEGO, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that company management will participate in fireside chats at the 6th Annual Evercore ISI HealthCONx Conference in Miami, Florida and the Piper Sandler 35th Annual Healthcare Conference in New York City.
2023-10-23 10:34:06 - Zacks Investment Research
What Makes Crinetics Pharmaceuticals, Inc. (CRNX) a Good Fit for 'Trend Investing'
Crinetics Pharmaceuticals, Inc. (CRNX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
2023-10-03 07:00:18 - InvestorPlace
7 Speculative Stocks Set to Explode Higher
As economic and stock market uncertainty looms, you may think at first that now is not a great time to be dabbling in speculative stocks. Yet, while the broad market may be experiencing turbulence right now, there are several stocks benefiting from company-specific catalysts that outweigh the macro issues.